Interestingly, an IL-2/IL-15 mimic, i.e. N215, was produced by state-of-the-art de novo computational and experimental protein design recently (Silva et al., 2019), which fully eliminated the binding site and dependency on IL-2Rα while enhancing the agonistic activity toward IL-2Rβγ, suggesting that N215 was valuable as a payload for NKG2A-targeted delivery for tumor immunotherapy. This evidence concerns the gene IL15 and neoplasm.